

1614

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/056,284
	Filing Date	January 23, 2002
	First Named Inventor	Weiss, Robert H.
	Group Art Unit	1614
	Examiner Name	Kwon, Brian Yong
Total Number of Pages in This Submission	Attorney Docket Number	023070-122900US


RECEIVED  
NOV 08 2002  
TECH CENTER 1601/2800

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form  <input type="checkbox"/> Fee Attached  <input checked="" type="checkbox"/> Second Preliminary Amendment  <input type="checkbox"/> After Final  <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application)  <input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition  <input type="checkbox"/> Petition to Convert to a Provisional Application  <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):  Return Postcard
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm and Individual name	Townsend and Townsend and Crew LLP Laurence J. Hyman Reg. No. 35,551	
Signature		
Date	10/31/02	

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date: 10/31/02	
Typed or printed name	Patricia Andrews
Signature	
Date	10/31/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

On Oct. 31, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Patricia Andrus

Attorney Docket No.: 023070-122900US  
Client Ref. No.: 2002-137-1

PATENT  
RECEIVED  
NOV 08 2002  
TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Robert H. Weiss

Application No.: 10/056,284

Filed: January 23, 2002

For: USE OF INHIBITORS OF  
SOLUBLE EPOXIDE HYDROLASE TO  
INHIBIT VASCULAR SMOOTH  
MUSCLE CELL PROLIFERATION

Examiner: Kwon, Brian Yong

Art Unit: 1614

SECOND  
PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Notice mailed October 15, 2002, please enter the following amendments and remarks.

IN THE SPECIFICATION:

Please replace page 4, line 22 and paragraph [18] with the following:

--**Figures 1a - 1e.** CDU inhibits proliferation in human VSM cells.

B1 [18] Human VSM cells were grown to 80-90% confluence and serum-starved (except where indicated) for 1 day.--